Daratumumab maintenance after treatment with VTd w/DARA and ASCT in pts with NDMM: CASSIOPEIA Part 2
Frontiers | Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
Addition of daratumumab to treatment is beneficial in newly diagnosed myeloma patients - BJH
Ben Derman on X: "CASSIOPEIA MRD analysis: Take a look at the top two PFS curves for Dara-VTd vs. VTd among MRD-negative patients. Doesn't seem like sustained MRD-negativity behaves the same? For
Rahul Banerjee, MD, FACP on X: "My take on CASSIOPEIA #MMsm at @UCSFCancer trial today - thanks @ninashah33 @ManniMD1 @End_myeloma @bdermanmd @TMSchmidtMD for helpful teaching via Twitter 🙏 Any conclusions I'm missing?
Cureus | Efficacy of Daratumumab-Based Regimens Compared to Standard of Care in Transplant-Eligible Multiple Myeloma: A Meta-Analysis | Article
Impact of VTD or VRD induction on stem-cell collection a Impact of VTD... | Download Scientific Diagram
ROLE OF DARATUMUMAB IN NEWLY DIAGNOSED MULTIPLE MYELOMA.pptx
Navigating Treatment Options for Newly Diagnosed ASCT-Eligible MM in 2021: Induction & Standard (VCD, VTD, VRd, Dara-VTD), Upfront ASCT vs. Bortezomib, Len Maintenance Until Progression | VuMedi
Best Practice for Newly Diagnosed Myeloma Patients Eligible for Transplant: How Can We Optimize Therapy?
Cancers | Free Full-Text | Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020
CASSIOPEIA - Dara-VTd - Multiple Myeloma Clinical Trials
Multiple Myeloma Hub on X: "#ASCO21 | Patients treated with dara+VTd/dara achieved higher responses and MRD negativity rates. 📢Share your experience with dara+VTd! How might the CASSIOPEIA results impact other trials exploring
Maintenance therapies in Multiple Myeloma - ppt download
Ben Derman on X: "CASSIOPEIA MRD analysis: Take a look at the top two PFS curves for Dara-VTd vs. VTd among MRD-negative patients. Doesn't seem like sustained MRD-negativity behaves the same? For
Die Erstlinientherapie des Multiplen Myeloms – aktueller Stand und neue Entwicklungen
Vincent Rajkumar on X: "Philippe Moreau is rubbing it in! IFM accrued 1085 patient with Newly Diagnosed MM in to the Dara-VTD vs VTD trial in 2 years! Astounding! We cannot do
Vincent Rajkumar on X: "CASSIOPEIA trial maintenance results in myeloma: Main takeaway is that daratumumab maintenance provided ZERO benefit if daratumumab was given as induction/consolidation This PFS curve (blue versus yellow line)
CASSIOPEIA Trial of Dara-VTd in Transplant-Eligible Myeloma
PDF) Prognostic value of positron emission tomography/computed tomography in transplanteligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study
Cancers | Free Full-Text | Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies
Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma - ScienceDirect
